Printer Friendly

MAJORITY OF FDA PANEL SAYS SUPLEMENTAL-BST LABELING NOT 'SOUND POLICY'

 WASHINGTON, May 7 /PRNewswire/ -- The majority of an expert panel convened by the Food and Drug Administration agreed that the use of supplemental BST does not change milk or dairy products and that it would not be "sound public policy" to require disclosure. However, as instructed by FDA, the panel did not make any formal recommendations, nor were they asked to reach consensus.
 "It is extremely encouraging that the majority of the committee recognized that food from BST-supplemented cows is safe and unchanged and there's no compelling policy reason for mandatory labeling," said Tom McDermott, director of public affairs for Monsanto.
 Supplemental BST is under review by FDA. In 1985, FDA declared that milk and meat from BST-supplemented cows are safe for consumption. Since then, the world's leading health authorities, including the congressional Office of Technology Assessment, American Medical Association and American Dietetic Association, have confirmed supplemental BST safety.
 "Clearly, consumers should have an opportunity to learn more about how their food is produced, including the introduction of technological advancements," said McDermott. "But it's well established that food labels have an entirely different function and aren't an appropriate way to educate consumers on these issues."
 -0- 5/7/93
 /CONTACT: Tom McDermott of Monsanto, 314-694-3605/


CO: Monsanto ST: District of Columbia IN: AGR HEA SU:

TW-DC -- DC021 -- 6153 05/07/93 17:27 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 7, 1993
Words:224
Previous Article:OCC CLOSES CROWN NATIONAL BANK
Next Article:ASBESTOS CLASS ACTION REHEARING APPROVAL CLEARS THE WAY FOR NEW SETTLEMENT AGREEMENT FOR MANVILLE TRUST
Topics:


Related Articles
NFPA DECRIES PROPOSED 90-DAY BST MORATORIUM
FDA APPROVES SUPPLEMENTAL BST; DAIRY MANAGEMENT TOOL ENHANCES PRODUCTIVITY
Monsanto says 'trust me,' makes Bossie a cash cow.
Diving into the gene pool.
Experts back voluntary OTC switch for Claritin. (Urticaria Indication a Stumbling Block).
FDA panels vote against lovastatin going OTC: fears were expressed that the OTC version might be used by consumers with contraindicated conditions.
Panel weighs ESA dosing, hemoglobin targets.
Panel backs continued, limited ESA use in selected Oncology patients.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters